Marion Koerper, MD Professor Emerita on Recall
Department of Pediatric Hematology
School of Medicine University of California, San Francisco
(UCSF) School of Medicine
National Hemophilia Foundation
Jennifer Maahs, RN, PNP, MSN
Indiana Hemophilia and Thrombosis Center
Celynda G. Tadlock, PharmD, MBA
Vice President Pharmacy Business Development, Aetna
President, Coventry Prescription Management Serivces, Inc.
Hemophilia Quick Facts
- Because of high health care expenditures for hemophilia (mean per patient cost in a commercial population is $155,000/year and $697,000/year for a patient with inhibitors), some health plans have increased cost sharing between insurers and patients with the patient assuming a larger amount of the costs.
- High cost-sharing requirements (i.e., use of co-insurance) for hemophilia therapies, compared to fixed copayment, may put patients with hemophilia at risk for not being able to afford treatment.
- A specialty tier (Tier IV) can have a co-insurance from 25% - 33% of the cost of clotting factor therapies, placing a higher amount of the financial burden on patients with hemophilia versus healthy patients.